Table 3.
The comparison of various ctDNA detection methods.
Type | Technique | Stability | Sensitivity | Cost | Target | Features |
---|---|---|---|---|---|---|
ARMS-based | ARMS | Mediate | Low | Low | Single gene mutation | Convenient, easy-operation |
Super-ARMS | Higher sensitivity than ARMS | |||||
dPCR-based | ddPCR | High | High | Low | Single gene mutation | Available for the clinic |
BEAMing | Definite ctDNA-quantification | |||||
NGS-based | TAM-Seq | High (influenced by laboratory level) |
High | High | Multiple gene mutations | Less cost and time, and lower sensitivity than other NGS-based methods |
Safe-SeqS | Identification of rare genetic mutations | |||||
CAPP-Seq | “Filter”; relatively high sensitivity | |||||
iDES | Higher sensitivity than CAPP-Seq | |||||
TEC-Seq | Deep sequencing; potential in the early-diagnosis when no symptoms occur | |||||
Mass spectrometry | MassARRAY | – | Mediate | Mediate | Multiple gene mutations | Less range than NGS-based methods |
Others | EFIRM | – | Mediate | Low | Multiple gene mutations | Short time; easy-operation |
ARMS, amplification refractory mutation system; PCR, polymerase chain reaction; ddPCR, droplet- based digital PCR; BEAMing, breads, emulsification, amplification and magnetics; TAM-Seq, tagged-amplicon sequencing; Safe-SeqS, safe sequencing system; CAPP-Seq, cancer personalized profiling by deep sequencing; iDES, integrated digital error suppression; TEC-Seq, targeted error correction sequencing; EFIRM, electric field-induced release and measurement.